Deborah Mash, CEO of DemeRx, is a true pioneer in the psychedelic field, having dedicated over 30 years to the research, development, and legalization of ibogaine for addiction. This fascinating conversation delves into the science, experience, and safety behind ibogaine's "neurochemical reset" as well as navigating the US drug regulatory system and intellectual property. Hear about the exciting clinical trials underway through DemeRx's partnership with ATAI Life Sciences and Deborah's predictions for ibogaine's legal future.